Kriya Therapeutics: Funding, Investors & Team (Sep 2026)
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. Kriya targets conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate human tissues. Kriya's team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. Kriya uses algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases.
Kriya Therapeutics has raised $914M across 5 funding rounds on record, the most recent a Series C of $313M announced in Aug 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kriya Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2025.
Kriya Therapeutics Funding Rounds
Kriya Therapeutics raised $80.5M in an undisclosed round announced in May 2020.
1.2 years later, a Series B of $100M was announced in Jul 2021.
10 months later, a Series C of $270M was announced in May 2022.
1.2 years later, a Series C of $150M was announced in Jul 2023.
2.1 years later, a Series C of $313M was announced in Aug 2025.
Kriya Therapeutics Founders and Leadership Team
Contact details for the Kriya Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Kriya Therapeutics Funding Compared to Other Biotechnology Startups
Kriya Therapeutics' latest round of $313M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kriya Therapeutics in Biotechnology and Redwood City
Companies Similar to Kriya Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Kriya Therapeutics Funding FAQs
What does Kriya Therapeutics do?
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. Kriya targets conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate human tissues. Kriya's team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. Kriya uses algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases.
How much funding has Kriya Therapeutics raised?
Kriya Therapeutics has raised $914M across 5 rounds on record. The most recent is a Series C of $313M announced in Aug 2025.
When did Kriya Therapeutics last raise funding?
Kriya Therapeutics' most recent funding round on record is a Series C of $313M, announced in Aug 2025.
Who is the CEO of Kriya Therapeutics?
Shankar Ramaswamy is listed as CEO at Kriya Therapeutics.
Where is Kriya Therapeutics headquartered?
Kriya Therapeutics is based in Redwood City, California, United States.
How many employees does Kriya Therapeutics have?
Kriya Therapeutics is in the 101-250 employee band.
How does Kriya Therapeutics' funding compare to other Biotechnology startups?
Kriya Therapeutics' latest round of $313M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Kriya Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kriya Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.